DUBLIN--(BUSINESS WIRE)--The "Non-Antibody Protein Scaffolds: Drugs and Diagnostics Market, 2017-2030" report has been added to Research and Markets' offering.
The Non-Antibody Protein Scaffolds: Drugs and Diagnostics Market, 2017-2030' report provides a comprehensive study of the current market landscape of non-antibody protein scaffolds, and related drugs and diagnostics, featuring an elaborate discussion on the likely future potential of this upcoming market. Over the past few years, this burgeoning field of research has captured the interest of several players in the pharmaceutical industry.
One of the key objectives of this report was to evaluate the current opportunity and the future potential of the non-antibody protein scaffolds market. Based on various parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2017-2030.
In addition, we have provided the likely distribution of the market based on end-use (therapeutic agents and diagnostic agents), key therapeutic areas (genetic disorders, eye disorders, autoimmune disorders, oncology and others), and non-antibody protein scaffold technologies. To account for the uncertainties associated with the development of non-antibody protein scaffold based drugs / diagnostics and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.
The opinions and insights presented in the report were also influenced by discussions with senior stakeholders in the industry. These include Alastair Smith (CEO, Avacta), Kyu-Tae-Kim (Director, AbClon), Ratmir Derda (Assistant Professor, University of Alberta) and Aditya Pandey (Postdoctoral Fellow, University of Toronto).
Key Topics Covered:
2. Executive Summary
4. Non-Antibody Protein Scaffolds: A Detailed Comparison
5. Market Overview
6. Drug / Diagnostic Agents: Profiles
7. Market Forecast
8. Recent Collaborations
9. Key Insights
11. Interview Transcripts
12. Appendix 1: Tabulated Data
13. Appendix 2: List of Companies and Organizations
For more information about this report visit https://www.researchandmarkets.com/research/5dwj4v/nonantibody